Other antithrombotic agents, in special the direct inhibitors of factor Xa, apixaban and rivaroxaban, have also demonstrated ability to attenuate lung injury [210, 211], could be potential candidates for the second and third stages of COVID-19, and rivaroxaban is being currently tested for COVID-19 in four clinical trials [212–215]. This evidence concerns the gene F10 and COVID-19.